Gilead Sciences exercised its option to exclusively license KT-200, a preclinical oral CDK2 molecular glue degrader program developed by Kymera Therapeutics. Under the licensing agreement, Gilead’s decision triggers additional milestone payments and expands its pipeline in oncology with a mechanism aimed at degrading rather than inhibiting CDK2. Kymera previously secured the underlying data package and selected a development candidate with Gilead’s collaboration. The deal structure gives Gilead global rights to KT-200 while Kymera prepares for the baton pass as Gilead advances IND-enabling studies. The licensing underscores how Big Pharma continues to add “molecular glue” differentiation to crowded oncology target landscapes, especially as CDK4/6 approaches have delivered benefits but faced progression and resistance. For investors, the KT-200 move adds another preclinical asset to Gilead’s degraders strategy and signals continued urgency to diversify into degradation platforms beyond monoclonal antibody and ADC-heavy pipelines.